Last $0.87 USD
Change Today -0.0301 / -3.34%
Volume 119.9K
DARA On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 3:58 PM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

dara biosciences inc (DARA) Key Developments

DARA BioSciences, Inc Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-12-2014 10:00 AM

DARA BioSciences, Inc Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-12-2014 10:00 AM. Venue: The Encore at Wynn Las Vegas, 3121 Las Vegas Blvd. South, Las Vegas, NV 89109, United States. Speakers: David J. Drutz, Executive Chairman and Chief Medical Officer.

DARA BioSciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

DARA BioSciences Inc. reported earnings results for the second quarter and six months ended June 30, 2014. For the quarter, net product Revenue was $409.4 million compared to $76.9 million a year ago. Net loss attributed to controlling interest was $2,583.1 million compared to $2,554.2 million a year ago. For the six months, net product Revenue was $570.9 million compared to $98.1 million a year ago. Net loss attributed to controlling interest was $5,241.1 million compared to $5,076.8 million a year ago.

DARA BioSciences, Inc to Report Q2, 2014 Results on Aug 12, 2014

DARA BioSciences, Inc announced that they will report Q2, 2014 results After-Market on Aug 12, 2014

DARA BioSciences, Inc, Q2 2014 Earnings Call, Aug 13, 2014

DARA BioSciences, Inc, Q2 2014 Earnings Call, Aug 13, 2014

DARA BioSciences, Inc Announces Executive Changes

DARA BioSciences Inc. announced that its board of directors has appointed current President and Chief Operating Officer (COO) Christopher G. Clement to President and Chief Executive Officer (CEO), effective immediately. David J. Drutz, M.D., the company's current CEO and Chief Medical Officer (CMO), will transition to the Executive Chairman of the Board of Directors while continuing to serve as CMO. In these roles, Dr. Drutz will provide ongoing leadership to DARA's strategic planning, business development and educational product support activities relative to the customers and sales organization. Haywood D. Cochrane Jr. will assume the role of Vice Chairman. Haywood D. Cochrane Jr. will assume the role of Vice Chairman. In his role as Executive Chairman and CMO, Dr. Drutz will help guide the future strategy and direction of the company. Mr. Clement joined DARA in 2012 with the acquisition of Oncogenerix Inc. Prior to founding Oncogenerix, Mr. Clement served as President and CEO of Savient Pharmaceuticals Inc., where he played an instrumental role in refocusing and specializing the business and driving a substantial increase in valuation. He also served as Chairman and CEO of Epicyte Pharmaceutical, as well as Executive VP, Senior VP and Chief Marketing Officer at Ares-Serono Group.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DARA:US $0.87 USD -0.0301

DARA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
PlasmaTech Biopharmaceuticals Inc $10.00 USD -1.00
View Industry Companies
 

Industry Analysis

DARA

Industry Average

Valuation DARA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.8x
Price/Book 0.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DARA BIOSCIENCES INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.